We found that, similar to the TCGA Pan-Cancer cohort, at least ten METTLs (e.g. METTL1, METTL2A, METTL2B, EEF1AKNMT) showed high-level amplifications in more than 2% of CCLE lines (Supplementary Table S12). Here, METTL2B is linked to cancer.